Scilex Holding Company (SCLX) - Net Assets
Based on the latest financial reports, Scilex Holding Company (SCLX) has net assets worth $-254.07 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($293.63 Million) and total liabilities ($547.71 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible equity quality of Scilex Holding Company to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-254.07 Million |
| % of Total Assets | -86.53% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Scilex Holding Company - Net Assets Trend (2020–2025)
This chart illustrates how Scilex Holding Company's net assets have evolved over time, based on quarterly financial data. See Scilex Holding Company liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Scilex Holding Company (2020–2025)
The table below shows the annual net assets of Scilex Holding Company from 2020 to 2025. For live valuation and market cap data, see Scilex Holding Company stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-211.75 Million | -9.92% |
| 2024-12-31 | $-192.64 Million | -11.39% |
| 2023-12-31 | $-172.94 Million | -577.22% |
| 2022-12-31 | $36.24 Million | +116.19% |
| 2021-12-31 | $-223.88 Million | -58.01% |
| 2020-12-31 | $-141.68 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Scilex Holding Company's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 65766000100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.00K | % |
| Other Comprehensive Income | $-5.80 Million | % |
| Other Components | $719.81 Million | % |
| Total Equity | $-207.78 Million | 100.00% |
Scilex Holding Company Competitors by Market Cap
The table below lists competitors of Scilex Holding Company ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
VHM Ltd
AU:VHM
|
$48.62 Million |
|
Lay Hong Bhd
KLSE:9385
|
$48.62 Million |
|
Bluebird bio Inc
NASDAQ:BLUE
|
$48.67 Million |
|
ConvaTec Group PLC
LSE:CTEC
|
$48.67 Million |
|
Wooshin System
KO:017370
|
$48.57 Million |
|
Libental
TA:LBTL
|
$48.57 Million |
|
Metavista3D Inc.
V:DDD
|
$48.57 Million |
|
Auto Trader Group plc
LSE:AUTO
|
$48.57 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Scilex Holding Company's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -192,641,000 to -207,781,000, a change of -15,140,000.
- Net loss of 358,734,000 reduced equity.
- Other comprehensive income decreased equity by 12,120,000.
- Other factors increased equity by 355,714,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-358.73 Million | -172.65% |
| Other Comprehensive Income | $-12.12 Million | -5.83% |
| Other Changes | $355.71 Million | +171.2% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Scilex Holding Company's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $-35.15 | $6.94 | x |
| 2021-12-31 | $-58.98 | $6.94 | x |
| 2022-12-31 | $9.45 | $6.94 | x |
| 2023-12-31 | $-46.46 | $6.94 | x |
| 2024-12-31 | $-27.71 | $6.94 | x |
| 2025-12-31 | $-18.83 | $6.94 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Scilex Holding Company utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1185.78%
- • Asset Turnover: 0.08x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-10.75%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 0.00% | -201.69% | 0.29x | 0.00x | $-33.35 Million |
| 2021 | 0.00% | -282.35% | 0.40x | 0.00x | $-66.04 Million |
| 2022 | -64.47% | -61.43% | 0.44x | 2.39x | $-26.99 Million |
| 2023 | 0.00% | -244.59% | 0.46x | 0.00x | $-97.04 Million |
| 2024 | 0.00% | -128.66% | 0.61x | 0.00x | $-53.54 Million |
| 2025 | 0.00% | -1185.78% | 0.08x | 0.00x | $-337.96 Million |
Industry Comparison
This section compares Scilex Holding Company's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $7,856,844,400
- Average return on equity (ROE) among peers: 37.91%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Scilex Holding Company (SCLX) | $-254.07 Million | 0.00% | N/A | $48.60 Million |
| AbbVie Inc (ABBV) | $3.94 Billion | 130.39% | 12.45x | $356.49 Billion |
| Amgen Inc (AMGN) | $933.70 Million | 38.30% | 0.47x | $184.15 Billion |
| Amarin Corporation PLC (AMRN) | $-88.45 Million | 0.00% | 0.00x | $315.59 Million |
| AstraZeneca PLC (AZN) | $39.17 Billion | 15.20% | 1.58x | $282.04 Billion |
| AstraZeneca PLC (AZN) | $14.04 Billion | 15.34% | 3.32x | $275.88 Billion |
| Biogen Inc (BIIB) | $74.90 Million | -25.50% | 0.15x | $27.74 Billion |
| Bristol-Myers Squibb Company (BMY) | $6.57 Billion | 43.38% | 1.24x | $112.89 Billion |
| Gilead Sciences Inc (GILD) | $297.29 Million | -22.37% | 0.47x | $155.64 Billion |
| GlaxoSmithKline PLC ADR (GSK) | $1.27 Billion | 157.62% | 5.56x | $111.15 Billion |
| Johnson & Johnson (JNJ) | $12.36 Billion | 26.73% | 0.74x | $564.26 Billion |
About Scilex Holding Company
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve… Read more